Retrophin to buy Orphan Tech for $90M upfront

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 22, 2020 at 11:32 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via Retrophin (NASDAQ:RTRX) has agreed to acquire privately-held Orphan Technologies and add OT-58, a novel enzyme replacement therapy in Phase 1/2 trial for the treatment of classical homocystinuria (HCU), a rare metabolic disorder characterized by elevated levels of plasma homocysteine that can lead to life-threatening thrombotic events.

    article source